Historical Stock Price
SRRA historical stock prices picture
SRRA (SRRA) has the following price history information. Looking back at SRRA historical stock prices for the last five trading days, on June 27, 2022, SRRA opened at $54.95, traded as high as $55.05 and as low as $54.93, and closed at $54.95. Trading volume was a total of 326.70K shares. On June 28, 2022, SRRA opened at $54.96, traded as high as $55.09 and as low as $54.95, and closed at $54.96. Trading volume was a total of 281.50K shares. On June 29, 2022, SRRA opened at $54.95, traded as high as $55.09 and as low as $54.94, and closed at $54.97. Trading volume was a total of 594.60K shares. On June 30, 2022, SRRA opened at $54.98, traded as high as $55.17 and as low as $54.98, and closed at $54.99. Trading volume was a total of 862.80K shares. On July 01, 2022, SRRA opened at $54.99, traded as high as $54.99 and as low as $54.99, and closed at $54.99. Trading volume was a total of 0 shares.

SRRA Historical Stock Prices By Date:

SRRA historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into SRRA shares, starting with a $10,000 purchase of SRRA, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 01/11/2017
End date: 07/01/2022
Start price/share: $56.80
End price/share: $54.99
Dividends collected/share: $0.00
Total return: -3.19%
Average Annual Total Return: -0.59%
Starting investment: $10,000.00
Ending investment: $9,681.58
Years: 5.47
Date Open High Low Close Volume
06/27/2022 $54.95 $55.05 $54.93 $54.95 326.70K
06/28/2022 $54.96 $55.09 $54.95 $54.96 281.50K
06/29/2022 $54.95 $55.09 $54.94 $54.97 594.60K
06/30/2022 $54.98 $55.17 $54.98 $54.99 862.80K
07/01/2022 $54.99 $54.99 $54.99 $54.99 0
Sierra Oncology is a late-stage biopharmaceutical company focused on therapies that treat cancer. Co.'s focus is the development and commercialization of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is a small-molecule inhibitor of JAK1 (Janus kinase 1), JAK2 (Janus kinase 2) and ACVR1 (Activin A receptor type 1), under development for treatment of patients with myelofibrosis. Co. has conducted a review of data from the two Phase 3 trials of momelotinib, versus ruxolitinib and best available therapy, as well as GS-US-352-1672, a Phase 2, open-label, translational biology trial of momelotinib in transfusion-dependent subjects with myelofibrosis.
Date Close
06/27/2022$54.95
06/28/2022$54.96
06/29/2022$54.97
06/30/2022$54.99
07/01/2022$54.99
SRRA is categorized under the Healthcare sector; below are some other companies in the same sector:

SRTS Historical Stock Prices
SSH Historical Stock Prices
SSKN Historical Stock Prices
SSRG Historical Stock Prices
SSY Historical Stock Prices
STAA Historical Stock Prices
STE Historical Stock Prices
STEM Historical Stock Prices
STJ Historical Stock Prices
STML Historical Stock Prices

Also explore: SRRA shares outstanding history

Email EnvelopeFree SRRA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


SRRA Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.